What is Chronic myelogenous leukemia (CML)

Chronic myelogenous leukemia (CML) is a type of cancer that affects the blood and bone marrow. It is characterized by the overproduction of abnormal white blood cells called myeloid cells. CML usually progresses slowly, and it is often diagnosed during routine blood tests.

The underlying cause of CML is a genetic mutation known as the Philadelphia chromosome, which leads to the production of an abnormal protein called BCR-ABL. This protein promotes the uncontrolled growth of myeloid cells.

Common symptoms of CML include fatigue, weakness, weight loss, night sweats, and an enlarged spleen. However, some individuals may not experience any symptoms in the early stages of the disease.

Treatment options for CML have significantly improved in recent years. Targeted therapy drugs, such as tyrosine kinase inhibitors (TKIs), are commonly used to manage the disease. These medications specifically target the BCR-ABL protein, helping to control the growth of cancer cells and improve long-term outcomes.

Regular monitoring and follow-up with healthcare professionals are crucial for individuals with CML to ensure the effectiveness of treatment and manage any potential side effects.